MedTrace Logo

Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method

NCT04429620 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-06-25

No results posted yet for this study

Summary

Prospective assay for SARS-CoV-2 antibody detection indirectly by immunofluorescence: SARS-CoV2 IIF method

Conditions

  • Sars-CoV2

Interventions

DIAGNOSTIC_TEST

Immunfluorescence

Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.

Sponsors & Collaborators

  • Bilogical Research Centre, Szeged

    collaborator UNKNOWN

  • Szeged University

    lead OTHER

Principal Investigators

  • Katalin Burián, MD · University of Szeged, Institute of Clinical Microbilogy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04429620 on ClinicalTrials.gov